Research programme: Alzheimer's disease therapies - NicOx

Drug Profile

Research programme: Alzheimer's disease therapies - NicOx

Alternative Names: NCX 2057; NCX 2213

Latest Information Update: 16 May 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NicOx
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Jul 2004 Preclinical trials in Alzheimer's disease in Italy (unspecified route)
  • 23 Jul 2004 Data presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2004) have been added to Pharmacodynamics section
  • 17 Jul 2000 Preclinical development for Alzheimer's disease in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top